Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

Baykara, Meltem; Benekli, Mustafa; Ekinci, Özgür; Irkkan, Sultan Çiğdem; Karaca, Halıt; Demirci, Umut; Akıncı, Muhammed Bülent; Ünal, Olçun Ümit; Dane, Faysal; Türköz, Fatma Paksoy; Balakan, Ozan; Eser, Eylem Pınar; Öztürk, Selçuk; Özkan, Metin; Öksüzoğlu, Berna; Sevinç, Alper; Demir, Neclå; Harputluoğlu, Hakan; Yalçın, Bülent; Coşkun, Uğur; Üner, Aytuğ; Özet, Ahmet; Büyükberber, Süleyman

doi:10.1007/s11605-015-2888-y

Cited by 21 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies showing HER2 amplification or overexpression in 8-54% of GC, especially in intestinal type and distal GC (5). In our recent study, HER2 positivity was 13.7% in Turkish patients (6) Trastuzumab is a humanized monoclonal antibody directed at the HER2 (7). In the trastuzumab for GC (ToGA) trial, trastuzumab-based therapy demonstrated a significant OS benefit in patients with HER2-positive advanced GC (8).…”

Section: Introductionmentioning

confidence: 73%

“…The reason of this may be the differences in the study populations, the difference of HER2 expression validated HER2 scoring systems. HER2 positivity was 22.1% of all patients in the ToGA trial, and 13.7% of Turkish patients (6,8). A significant discordance in HER2 status between primary cancer and metastatic sites has been reported in the breast cancer, bladder cancer and prostate cancer (16)(17)(18) The concordance between IHC and fluorescence in situ hybridization (FISH) method is less consistent than that observed in breast cancer (19) In the ToGA trial, the concordance between HER2 positivity detected by IHC and FISH was 87% and the differences were largely due to FISH-positive cases (8).…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

Gümüşay

Benekli

Ekinci

et al. 2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Determination of human epidermal growth factor receptor-2 status in advanced gastric cancer is important in clinical decision making. In the trastuzumab for GC trial, trastuzumab-based therapy demonstrated a significant overall survival benefit in patients with human epidermal growth factor receptor-2-positive advanced gastric cancer. Human epidermal growth factor receptor-2 discordance in gastric cancer primary and its metastases has been long debated. The aim of the study was to evaluate the rate of human epidermal growth factor receptor-2 discordance and its effect on treatment decisions in advanced gastric cancer. Methods: A total of 74 patients with advanced gastric cancer were included in the study. Both immunohistochemical staining and dual-color silver in situ hybridization were performed in all patients to evaluate the human epidermal growth factor receptor-2 status of the primary lesion and paired metastasis. Results: The assessment of human epidermal growth factor receptor-2 status with the immunohistochemical staining method and dual-color silver in situ hybridization revealed a discordance rate of 9.5 and 16.2%, respectively. However, this discordance was clinically meaningful in only one patient leading to a change in treatment decision. While this patient had a human epidermal growth factor receptor-2-negative status in primary tumor (immunohistochemical = 0, dual-color silver in situ hybridization = negative), the human epidermal growth factor receptor-2 status was positive for liver metastasis (immunohistochemical = 2+, dual-color silver in situ hybridization = positive). Trastuzumab was added to the chemotherapy regimen. Conclusions: In this study, we found a higher rate of human epidermal growth factor receptor-2 discordance between primary gastric tumor and metastatic lesions compared with the rates reported in previous studies. Detection of a human epidermal growth factor receptor-2-positive metastasis with a human epidermal growth factor receptor-2-negative primary tumor suggests that investigation of human epidermal growth factor receptor-2 is also required for the metastatic lesion and that trastuzumab could be administered in the case of a positive result.

show abstract

Section: Introductionmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 95%

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

Gümüşay

Benekli

Ekinci

et al. 2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011), and Jia et al who proved a significant association between HER2 overexpression, poor clinical outcome, and therapeutic drug resistance [17]. Whereas, Baykara et al [32] found that HER2 positive expression had no significant effect on median OS.…”

Section: Discussionmentioning

confidence: 98%

The Value of HER2 neu and EphA2 expressions in Gastric Adenocarcinoma Prognosis

Harb¹,

Atwa²,

Haggag³

et al. 2017

J Gastrointest Dig Syst

View full text Add to dashboard Cite

“…Overall, approximately 7 to 22 percent of esophagogastric cancers overexpress HER-2 [7][8][9]. HER-2 overexpression was positive immunohistocemically in 17.6% of 3264 specimen.…”

Section: The Rationale For Anti-her-2 Therapy In Gastric Cancermentioning

confidence: 97%

What to expect from HER-2 directed therapies in advanced gastric cancer?

Dane¹

2015

Marmara Medical Journal

Self Cite

View full text Add to dashboard Cite

Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.

show abstract

Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

Abstract: Rate of HER2 positivity is similar in Turkish patients with GC and GEJCs. HER2 positivity is associated with poor prognosis in patients with early-stage disease.

Cited by 21 publications

References 37 publications

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites

The Value of HER2 neu and EphA2 expressions in Gastric Adenocarcinoma Prognosis

What to expect from HER-2 directed therapies in advanced gastric cancer?

Contact Info

Product

Resources

About